SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is generating intense community buzz as the stock holds steady near the $5 level amid heavy short interest and anticipation surrounding upcoming data updates at the AACR conference. Long-term shareholders remain focused on the potential for clinical trial readouts to trigger a significant revaluation, while actively debating the impact of upcoming options expiration and the feasibility of an early trial halt based on therapeutic efficacy.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is experiencing significant volatility driven by intense retail interest and a high-stakes battle between long-term investors and short sellers amid speculation surrounding imminent regulatory news and global expansion efforts. The community is actively tracking option hedging, potential short squeeze dynamics, and the impact of institutional accumulation on the stock's price action.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is experiencing significant market interest following news that Greenland approved the transfer of a majority stake in the Tanbreez project, solidifying the company's control over a massive rare earth deposit. Community members are actively debating the potential for a short squeeze and long-term revaluation, with many highlighting the stock's strategic importance for Western supply chains and national security.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is experiencing significant market interest driven by an upsized capital raise of over 900 million dollars, which investors are viewing as a strategic growth catalyst to accelerate its transition into AI and high-performance computing data centers. The community is actively discussing the company's strong institutional backing and long-term infrastructure potential, with many traders closely monitoring the stock's ability to maintain upward momentum as it navigates near-term volatility and institutional share dilution.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Mining Inc

Cipher Mining is generating significant buzz as investors weigh its robust hyperscaler contract pipeline against recent sector-wide volatility and geopolitical headwinds. The community is actively debating the company's valuation gap compared to its peers, with many seeing the current price action as a potential accumulation zone while others express frustration over institutional selling patterns.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is trending as investors rally around reports of a pending U.S. executive order aimed at advancing ibogaine research for veteran mental health care. The community is actively debating the potential for a short squeeze, fueled by the company's low float and strong volume, while some skeptics express caution regarding the firm's history of dilution and trial timelines.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing a surge in retail interest driven by anticipation surrounding its prostate cancer therapy's clinical data and potential BLA filing. Community sentiment is mixed, with long-term investors highlighting the company's valuation gap relative to its pipeline potential, while skeptics focus on the lack of near-term catalysts and management's past performance.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid is trending as the stock experiences intense volatility following the appointment of a new CEO, a $1 billion capital raise, and expanded partnership plans with Uber. Despite these strategic moves, investors are actively debating the company's long-term viability, citing persistent dilution concerns and a challenging path to profitability.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing significant investor attention fueled by strategic partnerships with Nvidia, specifically regarding quantum computing AI tools and hardware integration. Community sentiment remains highly bullish, with many traders drawing parallels to other quantum sector leaders and anticipating a potential price re-rating as the company expands its space and defense contracts.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing intense volatility driven by a massive, sentiment-fueled short squeeze that has detached the stock price from its underlying fundamentals. While retail traders and some hedge funds are actively debating the sustainability of this rally versus a looming structural collapse, the conversation is dominated by intense speculation regarding potential share dilution, institutional exit strategies, and whether the momentum can persist toward historic highs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cannabis Operator GTBIF Stock Down 17% YTD: Should You Buy the Dip?

Green Thumb has lost 17% YTD as pricing pressure and competition weigh, but steady revenue growth and strong cash flow raise the question: Is the dip worth buying?

Cannabis Stock VRNO Rises 40% in a Year: Time to Buy, Sell or Hold?

Verano stock has surged more than 40% in a year amid U.S. marijuana rescheduling optimism, but revenue headwinds and rising competition may keep investors cautious.

Should You Buy GTBIF Stock After Marijuana Reclassification Order?

Shares of Green Thumb GTBIF jump nearly 35% on a marijuana rescheduling order, but pricing pressure and weak comps cloud the stock's near-term outlook.

Trump Orders Federal Action to Accelerate Cannabis Research Access

President Trump directed federal agencies Thursday to complete the marijuana rescheduling process initiated under the previous administration, focusing the executive action on expanding medical research opportunities for cannabis and CBD compounds.The executive order instructs the attorney general to finalize the reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act, a shift that administration officials characterized as removing bureaucratic obstacles to scientific study rather than addressing recreational use or criminal penalties.In a press ...

Cannabis plants grow in the greenhouse at Vireo Health's medical marijuana cultivation facility, August 19, 2016 in Johnstown, New York. (Photo by Drew Angerer/Getty Images)

Trump Moves A Step Closer To Reclassifying Marijuana As A Less Dangerous Drug — A Breakout Moment For Weed Industry?

The cannabis industry is enjoying renewed momentum under Trump, whose administration has adopted a notably more accommodative approach toward the drug and its related products.

Equity

<ul class="summary-bullets"><li>Bloomberg reported that the Centers for Medicare &amp; Medicaid Services (CMS), which runs the Medicare program, is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;</li><li>MSOS and YOLO, two key cannabis sector-focused funds, gained 3.4% and 2.7%, respectively.</li><li>The Trump administration seems to be backing cannabis as an industry, following its previous comments regarding CBD and reclassifying marijuana.</li></ul>Cannabis&nbsp;stocks advanced on Wednesday following a report speculating that certain U.S Medicare patients could soon be eligible to receive coverage for CBD under a new initiative.CBD, or cannabidiol, is a compound found in cannabis and used to treat sleep disorders, anxiety, pain, and inflammation. Some research suggests it may also treat cancer symptoms. The drug is sold as gummies, pet treats, and skincare supplements.<h2 class="st-heading-2">Cannabis Stocks Rally</h2>Tilray Brands’ shares rose 4.8%, while the over-the-counter stocks of Curaleaf Holdings, Trulieve Cannabis, and Green Thumb Industries gained between 2% to 5.6%. Shares of Innovative Industrial Properties, a real estate investment trust (REIT) that buys and leases specialized cannabis cultivation facilities, rose 1.1%.On Stocktwits, the retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/TLRY">TLRY</a> shifted to ‘extremely bullish’ from ‘bullish,’ while that for&nbsp;<a href="https://stocktwits.com/symbol/CURLF">CURLF</a> shifted to ‘bullish’ from ‘neutral.’ The sentiment was ‘bullish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">GTBIF</a>, and ‘bearish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">TCNNF</a> and&nbsp;<a href="https://stocktwits.com/symbol/IIPR">IIPR</a> as of the last reading.&nbsp;The&nbsp;<a href="https://stocktwits.com/symbol/MSOS">AdvisorShares Pure US Cannabis ETF (MSOS)</a>, which tracks U.S. cannabis companies exclusively, and the&nbsp;<a href="https://stocktwits.com/symbol/YOLO">AdvisorShares Pure Cannabis ETF (YOLO)</a>, which also tracks overseas companies and cannabis-adjacent businesses, rose 3.4% and 2.7%, respectively.<h2 class="st-heading-2">CMS Initaitive</h2>The rally came after Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-26/medicare-to-test-making-cbd-treatment-available-for-seniors">reported</a> that the Centers for Medicare &amp; Medicaid Services (CMS) is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;Details of the proposed program aren’t available, but an early version of the plan focused on seniors in oncology and palliative care settings, according to a summary viewed by the news agency.Unnamed sources told Bloomberg that Howard Kessler, a payments financier who has advocated for expanded CBD access, met with Health and Human Services Secretary Robert F. Kennedy Jr. about the issue last month<h2 class="st-heading-2">A Trump Boost?</h2>The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. Hemp-derived cannabidiol (CBD) could "revolutionize senior healthcare" by slowing disease progression and serving as an alternative to prescription drugs, Trump had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tilray-canopy-growth-cannabis-stocks-lose-high-premarket-after-surge-triggered-by-trumps-post/chDDTJ9R3BB">said</a> in a video post in September.The previous month, Trump said his administration was weighing a move to reclassify marijuana as a less dangerous drug under federal law.That said, doubts over cannabis efficacy in healthcare remain. A&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2836267">recent study</a> funded by the Food and Drug Administration suggested that prolonged use of CBD may cause liver toxicity, while other research suggests it can interfere with other medications, harm male reproductive health, and pose potential risks to children and pregnant women.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/holiday-shopping-could-soar-to-a-record-1-trillion-this-year-with-online-spending-blasting-to-new-highs/cL5eLqVREW6">Holiday Shopping Could Soar To A Record $1 Trillion This Year, With Online Spending Blasting To New Highs</a>

Tilray, IIPR, Trulieve, Other Cannabis Stocks Rally On Report Of Government Considering Adding CBD Treatment For Medicare Patients  

The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. 

<ul class="summary-bullets"><li>The provision bans online, gas station, and corner store sales of intoxicating hemp products, including delta-8, starting in 2026.</li><li>The rules are set to take effect in 2026, creating new compliance requirements for producers and retailers.</li><li>Tilray criticized the legislation, warning that it may prompt consumers to turn to unregulated alternatives.</li></ul>Cannabis stocks were trading lower in afternoon trade on Thursday amid broader weakness in the equities market after the U.S. government funding bill to end the shutdown included language tightening rules on hemp-derived THC products.Tilray Brands (TLRY) and Canopy Growth (CGC) shares fell more than 7%, while Green Thumb Industries (GTBIF) dipped 2.4%. Retail sentiment was ‘bearish’ around&nbsp;<a href="https://stocktwits.com/symbol/TLRY">Tilray’s stock</a>, according to Stocktwits data.&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">Green Thumb Industries’ stock</a> saw retail sentiment trending in ‘bullish’ territory over the past day, while retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/CGC">Canopy Growth’s stock</a> trended in the ‘extremely bullish’ zone.<h2 class="st-heading-2">New Hemp Rules Take Effect in 2026</h2>The funding legislation includes a provision banning the “unregulated sale of intoxicating hemp-based or hemp-derived products, including delta-8, from being sold online, in gas stations, and corner stores,” according to a Senate Appropriations Committee summary. The rules are set to take effect in 2026, creating new compliance requirements for producers and retailers.Tilray criticized the move, calling it a “misguided” step that could push consumers toward unregulated alternatives. “Prohibition and overly restrictive measures do not work,” the company said in a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tilray.com/news-releases/news-release-details/tilray-brands-condemns-misguided-prohibitionist-measures-and">statement</a> on Wednesday.<h2 class="st-heading-2">Retail Traders See Upside</h2>One Stocktwits user noted that the federal hemp ban increases the upside and that it’s a good opportunity to buy the dip.<stembedurl>https://stocktwits.com/techvested/message/636064141</stembedurl>Another user highlighted the optimism of investors buying cheap shares, anticipating that a rescheduling announcement for cannabis may be on the horizon later this year or next year.&nbsp;<stembedurl>https://stocktwits.com/Thumbszilla/message/636090102</stembedurl>The regulatory changes also weighed on broader cannabis-focused exchange-traded funds. AdvisorShares Pure U.S. Cannabis ETF (<a href="https://stocktwits.com/symbol/MSOS">MSOS</a>) fell more than 5% in afternoon trade on Thursday, while the Cambria Cannabis ETF (<a href="https://stocktwits.com/symbol/TOKE">TOKE</a>) dropped 1.4%.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/circle-stock-gains-after-jpmorgan-turns-bullish-cathie-woods-ark-invest-buys-the-dip/cLP9RYgRE3X">Circle Stock Gains Pre-Market After JPMorgan Turns Bullish, Cathie Wood’s Ark Invest Buys The Dip</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cannabis Stocks Drop As Shutdown Deal Tightens Hemp-THC Rules

The U.S. government funding bill to end the shutdown included language tightening rules on hemp-derived THC products.

Green Thumb Industries Inc. (GTBIF) Q3 Earnings and Revenues Top Estimates

Green Thumb Industries Inc. (GTBIF) delivered earnings and revenue surprises of +33.33% and +0.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Green Thumb Industries, Inc. engages in the manufacture and distribution of branded cannabis products. Its brands include RYTHM, Dogwalkers, Beboe, Good Green, Doctor Solomon’s, and &Shine. It operates through the Retail and Consumer Packaged Goods segments. The Retail segment focuses on retailing cannabis to patients and consumers. The Consumer Packaged Goods segment refers to the cultivation, production, and sale of cannabis products to retail stores. The company was founded by Benjamin Kovler and Max Cohen on February 18, 2002 and is headquartered in Chicago, IL.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.01	--	--	N/A
Q4 '25	$0.01	$0.35	2645.10%	BEAT
Q3 '25	$0.03	$0.10	225.58%	BEAT
Q2 '25	$0.04	-$0.01	-123.72%	MISSED
Q1 '25	$0.04	$0.04	-4.48%	MISSED

GTBIF
Green Thumb Industries

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest GTBIF News

GTBIFGreen Thumb Industries